Do you send Oncotype or Mammaprint as a predictive tool for patients with high grade (3/3) lymph node negative ER+ breast cancers?
1
1 Answers
Mednet Member
Medical Oncology · University of North Carolina
No it doesn't overrule. The key question is whether you would predicate chemotherapy use according to the genomic test estimates of prognosis with ET alone (oncotype, mammaprint, prosigna, EPclin etc).
